Status:
RECRUITING
Toripalimab Based Induction Chemotherapy Followed by De-escalation Protocols in HPV-related OPSCC
Lead Sponsor:
Fudan University
Conditions:
Oropharyngeal Carcinoma
Immune Checkpoint Inhibitor
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Human papillomavirus (HPV)-related oropharyngeal carcinoma are exquisitely radiosensitive. Several studies attempted to reduce the toxicities of treatments through reduced-dose radiation and showed pr...
Eligibility Criteria
Inclusion
- Histological diagnosis of squamous cell carcinoma of oropharynx with IHC p16
- positive or PCR HPV16 positive
- T1-2/N1-3M0（except T1N1M0 and single LN\<3cm）or T3-4N0-3M0 according to UICC/AJCC 8th staging system
- Age ≥18
- No prior anti-tumor treatment
- Karnofsky Performance Score (KPS)≥70
- Adequate blood supply
- Informed consent obtained
Exclusion
- Cannot take contrast-MRI imaging
- Pregnant
- Combined with other malignant tumor (except basal cell carcinoma of skin)
Key Trial Info
Start Date :
February 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2026
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT04867330
Start Date
February 1 2021
End Date
January 1 2026
Last Update
April 30 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fudan Universtiy Shanghai Cancer Centre
Shanghai, China, 200032